http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0446aef87403c91941425b311ae8b4c4
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Albanell |
| name | Joan Albanell |
| given-name | Joan |
| organization-name | 7Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; 8Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.; 11Universitat Pompeu Fabra, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.; Medical Oncology Service, Hospital del Mar, 08003 Barcelona, Spain.; Universitat Pompeu Fabra, 08003 Barcelona, Spain. Javier Cortés, Vall d'Hebron University Hospital; Joan Albanell, Hospital del Mar, Barcelona; Ana Lluch, Hospital Clinico Universitario, Valencia, Spain; Pierre Fumoleau, Centre Georges-François Leclerc, Dijon; Xavier Pivot, Centre Hospitalier Universitaire Jean Minjoz, Besançon; Veronique Servent, Centre Oscar Lambret, Lille, France; Giulia Valeria Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori; Luca Gianni, Istituto Nazionale, Milan; Pierfranco Conte,... Servei d'Oncologia Mèdica, Hospital del Mar, Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain Authors' Affiliations: 1Medical Oncology Service, Hospital del Mar; 2Cancer Research Program, IMIM; 3Autonomous University of Barcelona, Barcelona; 4Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain; 5The Cancer Therapeutics Unit/The Drug Development Unit, The Institute of Cancer Research/Royal Marsden Hospital, London, United Kingdom; 6SITEP, Department of Medicine, Institut Gustave Roussy, Villejuif, and University Paris-Sud, Paris; 7Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, CRCNA Nantes, France; 8F. Hoffmann-La Roche Ltd., Basel, Switzerland; 9F. Hoffmann-La Roche Ltd., Nutley, New Jersey; and 10.Roche Diagnostics GmbH, Penzberg, Germany; Authors' Affiliations: 1Medical Oncology Service, Hospital del Mar; 2Cancer Research Program, IMIM; 3Autonomous University of Barcelona, Barcelona; 4Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain; 5The Cancer Therapeutics Unit/The Drug Development Unit, The Institute of Cancer Research/Royal Marsden Hospital, London, United Kingdom; 6SITEP, Department of Medicine, Institut Gustave Roussy, Villejuif, and University Paris-Sud, Paris; 7Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, CRCNA Nantes, France; 8F. Hoffmann-La Roche Ltd., Basel, Switzerland; 9F. Hoffmann-La Roche Ltd., Nutley, New Jersey; and 10.Roche Diagnostics GmbH, Penzberg, Germany; Authors' Affiliations: 1Medical Oncology Service, Hospital del Mar; 2Cancer Research Program, IMIM; 3Autonomous University of Barcelona, Barcelona; 4Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain; 5The Cancer Therapeutics Unit/The Drug Development Unit, The Institute of Cancer Research/Royal Marsden Hospital, London, United Kingdom; 6SITEP, Department of Medicine, Institut Gustave Roussy, Villejuif, and University Paris-Sud, Paris; 7Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, CRCNA Nantes, France; 8F. Hoffmann-La Roche Ltd., Basel, Switzerland; 9F. Hoffmann-La Roche Ltd., Nutley, New Jersey; and 10.Roche Diagnostics GmbH, Penzberg, Germany 4Cancer Research Program, IMIM (Institut Hospital del Mar Investigacions Mediques), Hospital del Mar, Barcelona, Spain.; 6Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.; 10Pompeu Fabra University, Barcelona, Spain. Hospital del Mar, Medical Oncology , Barcelona , Spain 3Laboratory of Oncology Research, Medical Oncology Service, Vall d'Hebron Hospital, Barcelona, Spain; and Departments of Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain Universitat Pompeu Fabra, Barcelona, Spain Center for Biomedical Network Research on Cancer (CIBERONC), 28040 Madrid, Spain; Department of Medical Oncology, Hospital del Mar, 08003 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain 1Cancer Research Program, IMIM-Hospital del Mar;; 4Medical Oncology Service, Hospital del Mar-IMAS, Barcelona, Spain;; 6Department of Immunology, Fundación Jiménez Díaz;; 8Departament de Medicina, Universitat Autonoma de Barcelona, Bellaterra, Spain Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain;; Medical Oncology Department, Hospital del Mar, Barcelona, Spain;; Universitat Pompeu Fabra, Barcelona, Spain 5Medical Oncology Department, Hospital del Mar, Barcelona, Spain.; 6Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; 7Universitat Pompeu Fabra, Barcelona, Spain. Medical Oncology Department, Hospital del Mar–CIBERONC, Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Pompeu Fabra University, Barcelona, Spain 8Department of Medical Oncology, Hospital del Mar Medical Research Institute-IMIM and Pompeu Fabra University, Barcelona, Spain. 1Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.; 2Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.; 7Universitat Pompeu Fabra, Barcelona, Spain. Department of Radiology, Hospital St. Caterina, Girona, Spain. Programa de Recerca en Càncer IMIM (Institut Mar d'Investigacions Mèdiques) Barcelona Spain; Servei d'Oncologia Mèdica Hospital del Mar Barcelona Spain Authors' Affiliations: Departments of 1Pathology and 2Immunology, IIS-Fundación Jiménez Díaz, Madrid; 3Cancer Research Program; 4Microarray Core Facility (SAM), IMIM (Hospital del Mar Medical Research Institute); 5Department of Epidemiology and Evaluation, Hospital del Mar; 6Research Network on Health Services in Chronic Diseases (REDISSEC); 7Departments of Pathology, 8Medical Oncology, and 9Radiology Department, Hospital del Mar; and 10Universitat Pompeu Fabra, Barcelona, Spain; Authors' Affiliations: Departments of 1Pathology and 2Immunology, IIS-Fundación Jiménez Díaz, Madrid; 3Cancer Research Program; 4Microarray Core Facility (SAM), IMIM (Hospital del Mar Medical Research Institute); 5Department of Epidemiology and Evaluation, Hospital del Mar; 6Research Network on Health Services in Chronic Diseases (REDISSEC); 7Departments of Pathology, 8Medical Oncology, and 9Radiology Department, Hospital del Mar; and 10Universitat Pompeu Fabra, Barcelona, Spain; Authors' Affiliations: Departments of 1Pathology and 2Immunology, IIS-Fundación Jiménez Díaz, Madrid; 3Cancer Research Program; 4Microarray Core Facility (SAM), IMIM (Hospital del Mar Medical Research Institute); 5Department of Epidemiology and Evaluation, Hospital del Mar; 6Research Network on Health Services in Chronic Diseases (REDISSEC); 7Departments of Pathology, 8Medical Oncology, and 9Radiology Department, Hospital del Mar; and 10Universitat Pompeu Fabra, Barcelona, Spain 2Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.; 4Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.; 7Pompeu Fabra University, Barcelona, Spain. 1Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; 2Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.; 4Medical School, Universitat Pompeu Fabra (UPF), Barcelona, Spain. Medical Oncology Section, Hospital General Universitari Vall d'Hebron, Barcelona, Spain 3Medical Oncology Department, Hospital del Mar., Barcelona, Spain. Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain; Department of Medical Oncology, Hospital del Mar—CIBERONC, 08003 Barcelona, Spain; Department of Experimental and Health Sciences, Faculty of Medicine, Universitat Pompeu Fabra, 08002 Barcelona, Spain 1Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; 2Medical Oncology Department, Hospital del Mar- CIBERONC, Barcelona, Spain.; 12Universitat Pompeu Fabra, Barcelona, Spain. From the Oncology Service, Vall d’Hebron University Hospital; Dermatology Service, Hospital Clinic; Transfusio i Banc de Teixits, Vall d’Hebron Vall d’Hebron University Hospital, Barcelona, Spain; AstraZeneca Pharmaceuticals, Wilmington, DE; Oncology Service, M.D. Anderson Cancer Center, Houston, TX; Oncology Service, Harper Hospital, Detroit, MI; AstraZeneca Pharmaceuticals, Alderley Park; Department of Pharmacology, Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University,... Authors' Affiliations: 1Cancer Research Program, 2Epithelial to Mesenchymal Transition Laboratory, Cancer Research Program, IMIM; 3Consulting Service on Methodology for Biomedical Research; Departments of 4Oncology and 5Pathology, Hospital del Mar; 6Universitat Pompeu Fabra, Barcelona; Departments of 7Pathology and 8Oncology, IIS-Fundación Jiménez Díaz, Madrid, Spain; Authors' Affiliations: 1Cancer Research Program, 2Epithelial to Mesenchymal Transition Laboratory, Cancer Research Program, IMIM; 3Consulting Service on Methodology for Biomedical Research; Departments of 4Oncology and 5Pathology, Hospital del Mar; 6Universitat Pompeu Fabra, Barcelona; Departments of 7Pathology and 8Oncology, IIS-Fundación Jiménez Díaz, Madrid, Spain; Authors' Affiliations: 1Cancer Research Program, 2Epithelial to Mesenchymal Transition Laboratory, Cancer Research Program, IMIM; 3Consulting Service on Methodology for Biomedical Research; Departments of 4Oncology and 5Pathology, Hospital del Mar; 6Universitat Pompeu Fabra, Barcelona; Departments of 7Pathology and 8Oncology, IIS-Fundación Jiménez Díaz, Madrid, Spain 1Department of Medical Oncology and Laboratory of Experimental Oncology, Institut Clinic Malalties Hemato-Oncologiques, and; 3Medical Oncology Department and Experimental Therapeutics Research Unit, Hospital del Mar, Instituto Municipal de Investigación Médica, Instituto Municipal de Asistencia Sanitaria, Barcelona, Spain; 4GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; 17Hospital del Mar, Barcelona, Spain.; 20Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader, Barcelona; Servei d'Oncologia Médica, Hospital del Mar, Passeig Marítim, Barcelona; Pompeu Fabra University, Doctor Aiguader, Barcelona Cancer Research Program, Hospital del Mar Research Institute (IMIM), Medical Oncology Department, Hospital del Mar, E-08003 Barcelona, Spain Medical Oncology Department, Hospital del Mar de Barcelona, Spain. From the Departments of Medical Oncology, Pathology, and Radiology, Vall d'Hebron University Hospital, Barcelona, Spain; Bristol-Myers Squibb, Wallingford, CT, Waterloo, Belgium, and Madrid, Spain 1Cancer Research Program, IMIM, Hospital del Mar, Barcelona, Spain.; 3Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.; 9Universitat Pompeu Fabra, Barcelona, Spain. From the Vall d'Hebron University Hospital; Hospital Clinic, Barcelona; Instituto Valenciano de Oncologia; Universitat de Valencia, Hospital Clínico Universitario de Valencia and CESAT Valencia, Spain; and AstraZeneca, Wilmington, DE 2Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain.; 3Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.; 6Universitat Pompeu Fabra, Barcelona, Spain. 7Molecular Therapeutics and Biomarkers in Cancer Laboratory, Institut Hospital del Mar d'Investigacions Mèdiques, Hospital del Mar, Barcelona, Spain.; 8Medical Oncology Department, Hospital del Mar, Barcelona, Spain.; 9Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. Programa de Recerca en Càncer, IMIM (Institut Hospital del Mar de Investigacions Mèdiques), Barcelona, Spain; Servei de Oncologia Mèdica, Hospital del Mar, Barcelona, Spain Servei d'Oncologia Mèdica, Hospital del Mar, Barcelona, Spain. 96087@parcdesalutmar.cat. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 96087@parcdesalutmar.cat. CEXS Department, Pompeu Fabra University, Barcelona, Spain. 96087@parcdesalutmar.cat. CIOCC HM Delfos, Barcelona, Spain. 96087@parcdesalutmar.cat. 7Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; 8Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.; 9Universitat Pompeu Fabra, Barcelona, Spain. 1Laboratory of Experimental Oncology, Medical Oncology Department, Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; ICMHO, Laboratory of Oncology Research, Medical Oncology Service, Hospital Clinic i Provincial de Barcelona, Spain. albanell@clinic.ub.es Department of Medical Oncology, Institute of Hematology and Oncology (ICMHO), and the Department of Dermatology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Hospital Clínic, Barcelona, Spain. Hospital del Mar, Barcelona, Spain Medical Oncology Department, Hospital del Mar, Barcelona, Spain Hospital del Mar Medical Research Institute and Pompeu Fabra University, Barcelona, Spain GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, Barcelona, Spain; Pompeu Fabra University, Barcelona, Spain Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Medical Oncology Service, Hospital del Mar, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain hMedical Oncology Service, Hospital del Mar, Barcelona, Spain; iIMIM, Barcelona, Spain; jCEXS, Pompeu Fabra University, Barcelona, Spain From the Montabone Unit for New Drug Development, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto dei Tumori di Milano; Southern Europe New Drugs Organization, Milano, Italy; Oncology Institute of Southern Switzerland, Bellinzona; Kantonsspital St. Gallen, St. Gallen, Switzerland; Cancer Research Program, Institut Municipal d'Investigació Mèdica-Hospital del Mar, Barcelona, Spain; and ARIAD Pharmaceuticals, Cambridge, MA. Medical Oncology Service, Hospital del Mar, IMIM, Universitat Pompeu Fabra, The Centre of Networked Biomedical Cancer Research (CIBERONC), and Centro Oncológico Clara Campal-HM Delfos, Barcelona, Spain 1Hospital Clinic, Barcelona, Spain; Authors' Affiliations: 1Cancer Research Program, IMIM-Hospital del Mar; 2Pathology Service and 3Medical Oncology Service, Hospital del Mar-Parc de Salut MAR; 4Autonomous University of Barcelona; 5Medical Oncology Service, Hospital Clínic, Barcelona, Spain; 6Pathology Service, Fundacion Jimenez Diaz, Madrid, Spain; 7National Institute of Oncology and Radiobiology and 8Center of Molecular Immunology, Havana, Cuba; 9SENDO Foundation, Milan, Italy; and 10IOSI (Istituto Oncologico della Svizzera Italiana), Bellinzona, Switzerland; Authors' Affiliations: 1Cancer Research Program, IMIM-Hospital del Mar; 2Pathology Service and 3Medical Oncology Service, Hospital del Mar-Parc de Salut MAR; 4Autonomous University of Barcelona; 5Medical Oncology Service, Hospital Clínic, Barcelona, Spain; 6Pathology Service, Fundacion Jimenez Diaz, Madrid, Spain; 7National Institute of Oncology and Radiobiology and 8Center of Molecular Immunology, Havana, Cuba; 9SENDO Foundation, Milan, Italy; and 10IOSI (Istituto Oncologico della Svizzera Italiana), Bellinzona, Switzerland; Authors' Affiliations: 1Cancer Research Program, IMIM-Hospital del Mar; 2Pathology Service and 3Medical Oncology Service, Hospital del Mar-Parc de Salut MAR; 4Autonomous University of Barcelona; 5Medical Oncology Service, Hospital Clínic, Barcelona, Spain; 6Pathology Service, Fundacion Jimenez Diaz, Madrid, Spain; 7National Institute of Oncology and Radiobiology and 8Center of Molecular Immunology, Havana, Cuba; 9SENDO Foundation, Milan, Italy; and 10IOSI (Istituto Oncologico della Svizzera Italiana), Bellinzona, Switzerland |
Incoming Links
Total number of triples: 224.